[go: up one dir, main page]

MX2015013020A - Polimorfos de sovaprevir y metodos de fabricacion de los mismos. - Google Patents

Polimorfos de sovaprevir y metodos de fabricacion de los mismos.

Info

Publication number
MX2015013020A
MX2015013020A MX2015013020A MX2015013020A MX2015013020A MX 2015013020 A MX2015013020 A MX 2015013020A MX 2015013020 A MX2015013020 A MX 2015013020A MX 2015013020 A MX2015013020 A MX 2015013020A MX 2015013020 A MX2015013020 A MX 2015013020A
Authority
MX
Mexico
Prior art keywords
sovaprevir
polymorph
polymorphs
manufacture
methods
Prior art date
Application number
MX2015013020A
Other languages
English (en)
Inventor
Avinash Phadke
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of MX2015013020A publication Critical patent/MX2015013020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgación proporciona formas cristalinas de sovaprevir. Las formas cristalinas de sovaprevir comprenden un polimorfo de forma A, un polimorfo de forma B, un polimorfo de forma C, un polimorfo de forma D y un polimorfo de forma E. Los polimorfos de forma A, B, C, D y E presentan patrones de difracción de rayos X de polvo que tienen localizaciones de pico según las figuras 1, 4, 7, 10 y 13, respectivamente.
MX2015013020A 2013-03-15 2014-03-14 Polimorfos de sovaprevir y metodos de fabricacion de los mismos. MX2015013020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361786927P 2013-03-15 2013-03-15
PCT/US2014/028348 WO2014144087A1 (en) 2013-03-15 2014-03-14 Sovaprevir polymorphs and methods of manufacture thereof

Publications (1)

Publication Number Publication Date
MX2015013020A true MX2015013020A (es) 2016-06-10

Family

ID=50483591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013020A MX2015013020A (es) 2013-03-15 2014-03-14 Polimorfos de sovaprevir y metodos de fabricacion de los mismos.

Country Status (11)

Country Link
US (2) US9227952B2 (es)
EP (1) EP2970192A1 (es)
JP (1) JP2016513732A (es)
KR (1) KR20160005686A (es)
AU (1) AU2014227849A1 (es)
BR (1) BR112015023351A2 (es)
IL (1) IL241290A0 (es)
MX (1) MX2015013020A (es)
PH (1) PH12015502122A1 (es)
SG (1) SG11201507467VA (es)
WO (1) WO2014144087A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017448B1 (ru) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
GB201112231D0 (en) 2011-07-15 2011-08-31 Verdant Bioproducts Ltd Micro-organism
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483271B1 (en) 1989-07-19 1993-08-25 The Upjohn Company Peptides containing diamino-glycols as transition-state mimics
CA2137832C (en) 1992-06-12 2000-09-26 Dennis J. Hoover Inhibitors of angiotensin i chymase(s) including human heart chymase
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
CA2429359A1 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
PL213029B1 (pl) 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
ATE503764T1 (de) 2002-05-20 2011-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
DE60334205D1 (en) 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
KR100840715B1 (ko) 2002-05-28 2008-06-23 삼성전자주식회사 백 라이트 어셈블리 및 이를 갖는 액정 표시 장치
EP1408031A1 (en) 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
AU2004211637C1 (en) 2003-02-07 2010-08-19 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US6908901B2 (en) 2003-03-05 2005-06-21 Boehringer Ingelheim International, Gmbh Hepatitis C inhibitor peptide analogs
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
ES2297424T3 (es) 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh Compuestos inhibidores de la hepatitis c.
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
NZ544789A (en) 2003-07-18 2010-01-29 Vertex Pharma Dithia-azaspiro-nonane and decane derivatives as inhibitors of serine proteases
DE602004031645D1 (de) 2003-09-22 2011-04-14 Boehringer Ingelheim Pharma Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
RS54573B1 (sr) 2003-10-14 2016-06-30 F. Hoffmann-La Roche Ltd Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
CA2552319C (en) 2004-01-30 2012-08-21 Medivir Ab Hcv ns-3 serine protease inhibitors
ATE459638T1 (de) 2004-03-15 2010-03-15 Boehringer Ingelheim Int Verfahren zur herstellung makrocyclischer dipeptide, die sich für die behandlung von hepatitis-c-virusinfektionen eignen
BRPI0509467A (pt) 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
AP2461A (en) 2004-07-16 2012-09-14 Gilead Sciences Inc Antiviral compounds
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2577831A1 (en) 2004-09-17 2006-03-30 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic hcv protease inhibitors
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK1863833T3 (da) 2005-03-08 2013-12-02 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af makrocykliske forbindelser
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2006252519B2 (en) 2005-06-02 2012-08-30 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
WO2007009227A1 (en) 2005-07-20 2007-01-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
GEP20105124B (en) 2005-07-25 2010-11-25 Array Biopharma Inc Novel macrocyclic inhibitors of hepatitis c virus replication
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PL1934243T3 (pl) 2005-09-09 2011-10-31 Boehringer Ingelheim Int Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych
CN101415705B (zh) 2005-10-11 2011-10-26 因特蒙公司 抑制丙型肝炎病毒复制的化合物和方法
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA017448B1 (ru) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
EP1881002A1 (en) 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
EA200900969A1 (ru) 2007-01-08 2010-02-26 Феномикс Корпорейшн Макроциклические ингибиторы протеазы гепатита с
US20080207528A1 (en) 2007-02-01 2008-08-28 Syaulan Yang Hcv protease inhibitors
BRPI0922912A8 (pt) 2008-12-10 2018-01-02 Achillion Pharmaceuticals Inc peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral
TW201329025A (zh) * 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
BR112015023381A2 (pt) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido

Also Published As

Publication number Publication date
AU2014227849A1 (en) 2015-10-01
US20160176847A1 (en) 2016-06-23
JP2016513732A (ja) 2016-05-16
US9227952B2 (en) 2016-01-05
US20140275163A1 (en) 2014-09-18
IL241290A0 (en) 2015-11-30
US9540346B2 (en) 2017-01-10
SG11201507467VA (en) 2015-10-29
BR112015023351A2 (pt) 2017-07-18
KR20160005686A (ko) 2016-01-15
WO2014144087A1 (en) 2014-09-18
EP2970192A1 (en) 2016-01-20
PH12015502122A1 (en) 2016-01-25

Similar Documents

Publication Publication Date Title
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
EP3060541A4 (en) Methods and compounds for producing nylon 6,6
KR102320019B9 (ko) 히드라지닐-피롤로 화합물 및 콘쥬게이트 제조 방법
SG11201506149SA (en) Polyetheramines based on 1,3-dialcohols
IN2013MU00646A (es)
EP3037407A4 (en) Method for producing 1,5-pentadiamine
GB201611797D0 (en) Synthesising carbon compounds
SG11201507951SA (en) Method for producing 2,7-octadien-1-ol
GB2537220B (en) Processfor producing substitute natural gas
EP3060597A4 (en) Compounds and methods for producing nylon 6
MX2015012142A (es) Formas polimorfas de onapristona y metodos de uso.
EP3030516A4 (en) SYNTHESIS OF CORE CASE METAL SEMICONDUCTOR NANOMATERIALS
MX2016001641A (es) Ciclobutilcarboxamidas como nematicidas.
PT3131910T (pt) Utilização de um composto de fosforamidato de 1,3,5-triazina- 2-ilo na síntese de sofosbuvir
SI3004077T1 (sl) Novi spojini 3,4-dihidro-2H-izokinolin-1-on in 2,3-dihidro-izoindol-1-on
ZA201803250B (en) New 5-azido-5-deoxy-2 :3-isopropylidene-d-arabinose compounds; their method of manufacture and their use for the synthesis of ara-n3, kdo-n3 and 4ekdo-n3
HUE037141T2 (hu) Eljárás 1,1-dibróm-1-fluoretán elõállítására
IL258492A (en) A process for the synthesis of carbon nanotubes
SG11201604094VA (en) Method for producing 2,3-butanediol
SI3004076T1 (sl) Novi spojini 3,4-dihidro-2H-izokinolin-1-on in 2,3-dihidro-izoindol-1-on
IL251323A0 (en) Author compounds, methods for their preparation and their use
GB2520791B (en) Method of producing derivatives of 1,3,5-triarylbenzene
SG11201704711SA (en) Phosphite compound, method for producing the same and uses thereof
SMT201800106T1 (it) Metodo per la produzione di un composto di 4,4,7-trifluoro-1,2,3,4-tetraidro -5h-1-benzazepina e intermedio per la sua sintesi
GB201312753D0 (en) Methods of making the Dipole Work greater than the Magnetisation Energy